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INTRODUCTION
Prostate cancer (PCa) is the most common, newly diagnosed 
cancer in men.1 Choice of therapy is based on risk stratifica-
tion of the disease or the patient’s morbidity. Androgen depri-
vation therapy (ADT) represents a cornerstone of treatment 
for PCa.2 The association between androgen suppression and 
tumor regression was first described by Huggins3 in 1942, and 
the efficacy and usage of ADT for various stages of PCa have 
since been extensively studied. 
National Comprehensive Cancer Network (NCCN®) guide-
lines currently recommend ADT as the primary treatment for 
metastatic PCa.4 In addition, external irradiation combined 
with ADT in patients with locally advanced PCa improves both 
clinical disease-free and overall survival (OS), as compared to 
radiotherapy alone.5 Radical prostatectomy (RP) followed by 
immediate adjuvant ADT for lymph node-positive metastatic 
PCa also improves cancer-specific survival (CSS) and OS.6 The 
efficacy of ADT for the treatment of clinical localized PCa re-
mains controversial. Primary ADT does not improve survival 
in cases of localized PCa7; however, adjuvant ADT improves 
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Purpose: Androgen deprivation therapy (ADT) is used as a salvage treatment for men with biochemical recurrence (BCR) of 
prostate cancer (PCa) following initial radical prostatectomy (RP). The optimal time at which to begin salvage ADT (sADT) re-
mains controversial. In this retrospective study, we evaluated the efficacy of initiating sADT in patients before prostate-specific 
antigen (PSA) values met the clinical definition of BCR.
Materials and Methods: We identified 484 PCa patients who received sADT for BCR after RP. Median follow-up was 82 months. 
Propensity score matching was performed based on preoperative PSA level, pathologic T stage, and Gleason score. Patients were 
assigned to two groups of 169 patients each, based on PSA levels at the time of sADT: Group A (without meeting of the definition 
of BCR) and Group B (after BCR). Kaplan-Meier survival analyses and Cox regression analyses were performed. 
Results: The median PSA level at sADT initiation was 0.12 ng/mL in group A and 0.42 ng/mL in group B. Kaplan-Meier analyses 
showed that group A had favorable disease progression-free survival (DPFS) and distant metastasis-free survival (DMFS), but did 
not have better cancer-specific survival (CSS) than group B. In subgroup analyses, group A showed better CSS rates in the non-
organ confined PCa group. In Cox regression analyses, early sADT was associated significantly with DPFS and DMFS rates, how-
ever, did not correlate with CSS (p=0.107). 
Conclusion: Early sADT after RP improved DPFS and DMFS. Furthermore, early sADT patients demonstrated better CSS in non-
organ confined PCa.  
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CSS and systematic progression-free survival (PFS) after RP in 
node-positive PCa.8 ADT benefits patients with biochemical re-
currence (BCR) or non-metastatic PCa recurrence after local 
treatment, especially in high-risk PCa patients.9 While early ADT 
delays biochemical and clinical disease progression,10 however, 
the optimal prostate-specific antigen (PSA) levels for initiation 
of ADT as a salvage treatment for BCR are not well defined. 
In this retrospective study, we evaluated the impact of early 
salvage ADT (sADT) initiated in the presence of increasing PSA 
levels that did not yet meet the clinically-defined criteria for 
BCR. Our goal was to determine the optimal timing of ADT as 
a salvage treatment for BCR after RP to improve outcomes for 
these patients.
MATERIALS AND METHODS
Study population
After Institutional Review Board approval (4-2017-1206), we 
retrospectively reviewed medical records of 484 node-negative 
PCa (T1–T4, N0, and M0) patients who received sADT after RP, 
performed at Yonsei University Health System, from 1995 to 
2014. Patients with clinical distant metastasis or lymph node 
metastasis observed by lymph node dissection, and those who 
received neo-adjuvant therapy were excluded from the study. 
Salvage treatment was defined as ADT or radiotherapy initiat-
ed following rising PSA levels after RP. We considered ADT or 
radiotherapy administered in the absence of rising PSA levels 
after RP as adjuvant therapy, and excluded these patients from 
our analysis. The type and timing of sADT administered follow-
ing observation of rising PSA levels were determined by dis-
cretion of physicians. Clinical and pathologic variables as-
sessed for this study included age, body mass index (BMI), PSA 
level, risk classification, type of sADT, PSA doubling time, and 
pathologic outcomes. 
D’Amico risk classification for PCa was performed.11 PSA 
doubling time was calculated, based on PSA levels at the com-
mencement of sADT, compared to the last PSA level recorded 
prior to sADT. Data regarding mortality and cause of death 
were obtained from the Yonsei Cancer Registry Center data-
base at Severance Hospital. TNM stage was determined accord-
ing to the American Joint Committee on Cancer, 8th edition.12 
Table 1. Baseline Patient Characteristics (n=484)
Variable Early sADT (n=190) Delayed sADT (n=294) p value
Age (yr)     66 (60−71)    67 (63−70) 0.217 
BMI (kg/m2)  23.9 (22.2−26.1) 24.3 (22.6−25.8) 0.387 
Prostate volume measure by TRUS (mL)  28.5 (23.0−38.0) 29.0 (24.0−39.0) 0.461
PSA  (ng/mL)    8.3 (5.9−13.1) 11.8 (8.0−17.8) <0.001
PSA (categorical) <0.001
<20  174 (91.6)  230 (78.2)
≥20    16 (8.4)    64 (21.8)
D'Amico risk classification <0.001
Low    32 (16.8)    22 (7.5)
Intermediate    72 (37.9)    83 (28.2)
High    86 (45.3)  189 (64.3)
Pathologic T stage 0.323 
Organ confined (T2)    63 (33.2)    85 (28.9)
Non-organ confined (>T2)  127 (66.8)  209 (71.1)
Pathologic Gleason score 0.001
<8  154 (81.1)  198 (67.3)
≥8    36 (18.9)    96 (32.7)
Positive surgical margin  125 (65.8)  200 (68.0) 0.609
PSA at sADT (ng/mL) 0.12 (0.11−0.15) 0.50 (0.29−1.26) 0.021
Type of ADT 0.073
LHRH agonist or antagonist with anti-androgens  104 (54.7)  177 (60.2)
LHRH agonist or antagonist only    64 (33.7)    72 (24.5)
Anti-androgens only    22 (11.6)    45 (15.3)
PSA doubling time at ADT (month)   3.7 (1.9−7.5)   3.5 (1.7−6.9) 0.283
Salvage radiotherapy    29 (15.3)  103 (35.0) <0.001
PSA >0.2 ng/mL after sADT    47 (24.9)  175 (59.9) <0.001
BMI, body mass index; LHRH, luteinizing hormone-releasing hormone; PSA, prostate-specific antigen; sADT, salvage androgen deprivation therapy; TRUS, tran-
srectal ultrasonography.
Data are expressed as median (interquartile range) or n (%).
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Statistical analyses
We divided patients into two groups based on PSA level at the 
initiation of sADT. Group A (early sADT) included patients ad-
ministered sADT when PSA levels rose consecutively two or 
more times without meeting the clinical definition of BCR. BCR 
was defined as two consecutive increases in PSA levels >0.2 
ng/mL after RP.13 Group B (delayed sADT) included patients 
administered sADT after standard BCR criteria were reached. 
Propensity score matching was performed to adjust for con-
founders (preoperative PSA level, pathologic T stage (pT), and 
pathologic Gleason score after RP). We compared clinical and 
pathologic parameters of each group before and after propen-
sity score matching using Student-T tests and chi-square tests. 
Age, surgical margin status, type of ADT, and other parameters 
were compared in each group.
Kaplan-Meier survival analyses were performed to compare 
disease progression-free survival (DPFS), distant metastasis-
free survival (DMFS), and CSS between treatment groups. Sub-
groups included patients divided by risk classification (low/
intermediate vs. high-risk), Gleason score (<8 vs. ≥8), and T 
stage [organ confined (pT2) vs. non-organ confined (pT3 or 
4)]. Disease progression was defined as any progression of 
disease confirmed by radiologic evaluations, and distant me-
tastasis was defined as metastasis to bone, non-regional lymph 
nodes or other sites. Cancer-specific mortality (CSM) was de-
fined as death caused by PCa or PCa-related complications. 
Univariable and multivariable Cox regression analyses were 
performed to identify associations between clinical parameters 
and survival outcomes. All statistical analyses were performed 
using SPSS Statistics software version 23.0 (IBM Corp., Ar-
monk, NY, USA).
RESULTS
A total of 484 node-negative PCa patients who received sADT 
were evaluated for this study, and their characteristics are sum-
marized in Table 1. Of these patients, 190 received early sADT, 
while 294 received delayed sADT. Median follow-up duration 
was 82 months. Significantly more patients with delayed sADT 
had high-risk PCa (45.3% vs. 64.3%, p<0.001) and higher PSA 
levels preoperatively (8.3 ng/mL vs. 11.8 ng/mL, p<0.001) 
Table 2. Baseline Patient Characteristics after Propensity Score Matching (n=338)
Variable Early sADT (n=169)  Delayed sADT (n=169) p value
Age (yr)    66 (60−71)    66 (62−70) 0.208 
BMI (kg/m2) 23.9 (22.1−26.1) 24.1 (22.4−25.8) 0.262 
Prostate volume measure by TRUS (mL) 28.0 (23.0−38.0) 28.0 (23.0−35.0) 0.558
PSA  (ng/mL)   9.5 (6.2−14.0)   9.3 (6.4−13.0) 0.882
PSA (categorical) (ng/mL) 0.841 
<20  155 (91.7)  156 (92.3)
≥20    14 (8.3)    13 (7.7)
D'Amico risk classification 0.530 
Low    23 (13.6)    22 (13.0)
Intermediate    66 (39.1)    57 (33.7)
High    80 (47.3)    90 (53.3)
Pathologic T stage 0.817 
Organ confined (T2)    55 (32.5)    57 (33.7)
Non-organ confined (>T2)  114 (67.5)  112 (66.3)
Pathologic Gleason score 0.790 
<8  134 (79.3)  132 (78.1)
≥8    35 (20.7)    37 (21.9)
Positive surgical margin  117 (69.2)  111 (65.7) 0.486
PSA at sADT (ng/mL) 0.12 (0.11−0.16) 0.42 (0.27−1.10) 0.010 
Type of ADT 0.115
LHRH agonist or antagonist with anti-androgens    90 (53.3)  101 (59.8)
LHRH agonist or antagonist only    57 (33.7)    40 (23.7)
Anti-androgens only    22 (13.0)    28 (16.6)
PSA doubling time (month)   3.4 (1.9−6.1)   3.6 (1.7−7.9) 0.572
Salvage radiotherapy    26 (15.4)    60 (35.5) <0.001
PSA >0.2 ng/mL after sADT    45 (26.8)    96 (57.1) <0.001
BMI, body mass index; LHRH, luteinizing hormone-releasing hormone; PSA, prostate-specific antigen; sADT, salvage androgen deprivation therapy; TRUS, tran-
srectal ultrasonography.
Data are expressed as median (interquartile range) or n (%).
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compared to those with early sADT. Among delayed sADT pa-
tients, a pathologic Gleason Score ≥8 was observed more fre-
quently than in patients with early sADT (18.9% vs. 32.7%, 
p=0.001). 
Propensity score matching was used to adjust for confound-
ing variables, resulting in 169 patients being assigned to two 
treatment groups (Groups A and B) based on PSA levels at the 
time of sADT. Basic characteristics of these two groups are 
displayed in Table 2. No statistical differences were observed 
in age, BMI, risk classification, and surgical margin status be-
tween groups. The median PSA level at the initiation of sADT was 
0.12 ng/mL in group A and 0.42 ng/mL in group B (p=0.010). 
The majority of patients in both groups underwent similar 
treatment regimens which comprised of sADT with luteiniz-
ing hormone-releasing hormone (LHRH) agonist with or with-
out anti-androgens (Group A 87.0%, Group B 83.4%). Salvage 
radiotherapy was performed more frequently in group B than 
in group A (15.4% vs. 35.5%, p<0.001). After sADT, group A dem-
onstrated a significantly slower rate of PSA increase to levels 
above 0.2 ng/mL than did group B (26.8% vs. 57.1%, p<0.001). 
During the follow-up period, there were 17 cases of disease pro-
gression in group A and 49 cases in group B. Distant metasta-
sis was reported in four cases in group A and 24 cases in group 
B. A total of 11 deaths from PCa were recorded. There was one 
death from PCa in group A and 10 deaths in group B.
Kaplan-Meier analyses revealed that group A had a signifi-
cantly more favorable DPFS than group B, with 7-year DPFS 
rates of 87.3% and 73.3% (p=0.001), respectively, as shown in 
Fig. 1. Group A also demonstrated a significantly higher 7-year 
DMFS than group B (96.1% vs. 88.7%, p=0.001) as displayed in 
Fig. 2. The 7-year CSS rates of groups A and B were not signifi-
cantly different (98.9% vs. 96.3%, p=0.071) (Fig. 3); however, 
group A experienced fewer mortalities. In a subgroup analysis 
of patients with non-organ confined PCa, the early sADT group 
showed statistically favorable CSS compared to those receiving 
delayed sADT (p=0.042), as shown in Fig. 4. This was not ob-
served in other subgroups.
Univariable and multivariable Cox regression analyses re-
vealed several factors that were significantly associated with 
DPFS (Table 3). These included high-risk PCa [hazard ratio 
(HR) 2.272, 95% confidential interval (CI) 1.359−3.799], salvage 
radiotherapy (HR 0.447, 95% CI 0.274−0.730), and early sADT 
(HR 0.457, 95% 0.260−0.801). The results of univariable and 
multivariable Cox regression analyses for predictive factors of 
DMFS are presented in Table 4. These predictive factors includ-
ed pathologic Gleason score (HR 2.463, 95% CI 1.073−5.654), 
PSA doubling time (HR 0.875, 95% CI 0.773−0.990), and sal-
vage radiotherapy (HR 0.389, 95% CI 0.183−0.826). Early sADT 
(HR 0.244, 95% CI 0.084−0.714) was positively associated with 
DMFS. High-risk PCa (HR 9.550, 95% CI 1.049−86.947) and a 
pathologic Gleason score ≥8 (HR 3.688, 95% CI 1.009−13.484) 
correlated significantly with CSS, while early sADT was not 
overall predictive of CSS (Supplementary Table 1, only online). 
As shown in Supplementary Table 2 (only online), early sADT 
in non-organ confined PCa was not associated with CSS in 
Cox regression analysis, while only pathologic Gleason score 
was associated with CSS in non-organ confined PCa (HR 10.092, 
95% CI 1.930−52.785).
DISCUSSION
Current NCCN® guidelines recommend ADT for the treatment 
of advanced PCa.4 Immediate ADT has demonstrated benefits 
for patients with metastatic PCa in OS or CSS,14 as well as those 
with node-positive PCa following RP with pelvic lymph node 
dissection.6,15 In contrast, however, a population-based cohort 
study demonstrated that primary ADT is not associated with 
improved survival among men with localized PCa.7 Current 
guidelines do not recommend ADT for PCa without local de-
finitive treatment.4
The utility of ADT after local definitive treatment of clinically 
localized PCa remains unresolved in the current literature. A 
study performed by Siddiqui, et al.8 suggests that adjuvant ADT 
improves CSS and systemic PFS after RP in node-negative PCa. 
The benefits of ADT, however, are lost when treatment is initiat-
ed after BCR or systemic progression. In a study involving 2096 
PCa patients, Garcia-Albeniz, et al.16 suggest that ADT initiated 
within three months after PSA-only relapse results in similar 
survival to that observed with deferred ADT (initiated within 
three months after clinical progression). Furthermore, Duch-
esne, et al.17 report that immediate ADT improves OS and time 
to clinical progression for PCa patients after BCR following cu-
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Table 3. Univariate and Multivariate Analyses of Factors Associated with Disease Progression-Free Survival
Variable
Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value
Age 0.993 (0.958−1.029) 0.705 
BMI 0.949 (0.856−1.053) 0.327 
Prostate volume measure by TRUS 1.000 (0.981−1.019) 0.983 
Risk classification 0.002 0.002 
Low & intermediate 1 (ref) 1 (ref)
High 2.225 (1.332−3.716) 2.272 (1.359−3.799)
PSA 0.413 
<20 1 (ref)
≥20 1.387 (0.633−3.040)
Pathologic T stage 0.895 
Organ confined (T2) 1 (ref)
Non-organ confined (>T2) 0.966 (0.579−1.612)
Pathologic Gleason score 0.454 
<8 1 (ref)
≥8 1.240 (0.706−2.178)
Positive surgical margin 0.830 (0.502−1.370) 0.466 
PSA doubling time 0.972 (0.928−1.019) 0.242 
Salvage radiotherapy 0.396 (0.244−0.643) <0.001 0.447 (0.274−0.730) 0.001 
Early salvage ADT vs. delayed salvage ADT <0.001 0.002 
Delayed salvage 1 (ref) 1 (ref)
Early salvage 0.389 (0.223−0.677) 0.457 (0.260−0.801)
ADT, androgen deprivation therapy; BMI, body mass index; PSA, prostate-specific antigen; TRUS, transrectal ultrasonography.
Table 4. Univariate and Multivariate Analysis of Factors Associated with Distant Metastasis-Free Survival
Variable
Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value
Age 0.994 (0.940−1.050) 0.822 
BMI 1.000 (0.857−1.166) 0.999 
Prostate volume measure by TRUS 1.000 (0.971−1.029) 0.991 
Risk classification 0.005 0.073 
Low & intermediate 1 (ref) 1 (ref)
High 3.458 (1.464−8.170) 2.391 (0.922−6.203)
PSA 0.395 
<20 1 (ref)
≥20 0.421 (0.057−3.097)
Pathologic T stage 0.867 
Organ confined (T2) 1 (ref)
Non-organ confined (>T2) 1.070 (0.483−2.370)
Pathologic Gleason score 0.001 0.033 
<8 1 (ref) 1 (ref)
≥8 3.653 (1.737−7.686) 2.463 (1.073−5.654)
Positive surgical margin 0.556 (0.264−1.170) 0.122 
PSA doubling time 0.871 (0.779−0.975) 0.016 0.875 (0.773−0.990) 0.034 
Salvage radiotherapy 0.324 (0.154−0.682) 0.003 0.389 (0.183−0.826) 0.014 
Early salvage ADT vs. delayed salvage ADT 0.004 0.010 
Delayed salvage 1(ref) 1 (ref)
Early salvage 0.205 (0.071−0.593) 0.244 (0.084−0.714)
ADT, androgen deprivation therapy; BMI, body mass index; PSA, prostate-specific antigen; TRUS, transrectal ultrasonography.
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rative therapy in a randomized trial (TOAD trial). In yet another 
study, sADT for BCR following treatment for localized PCa 
was not associated with all-cause mortality or CSM; however, 
it was observed in a subgroup analysis that men with rapidly 
progressing disease have decreased all-cause mortality and 
CSM with sADT.18 Finally, in a recently published systematic 
review, van den Bergh, et al.9 suggest that early systemic hor-
monal therapy for non-metastatic recurrence should be re-
served for those patients with the highest risk of disease pro-
gression, defined by short PSA doubling time or high Gleason 
score. Clearly, these incongruous findings confound opportuni-
ties to optimize PCa therapy for patients with recurrent disease. 
Similarly, previously published studies, that seek to identify 
the ideal time to initiate sADT for BCR following RP, remain 
controversial. Based on a study of 1352 PCa patients who un-
derwent RP, Moul, et al.19 concluded that initiation of ADT in 
patients with PSA levels <5 ng/mL for treatment of “PSA-only 
recurrence” can delay clinical metastasis, and suggested that 
early ADT is associated with delayed clinical metastases in 
patients with high-risk cases, including those with a Gleason 
score of greater than 7 or a PSA doubling time shorter than 12 
months. The benefits of early ADT on clinical metastasis, how-
ever, were lost in the overall cohort and they did not further 
evaluate the impact of early ADT on OS or CSS. The benefits 
of early ADT, administered before disease progression, includ-
ing BCR, have previously been addressed by Siddiqui, et al.8 
who showed improved 10-year systemic PFS and 10-year CSS, 
while they did not suggest an optimal PSA value at which to 
initiate ADT in a salvage treatment setting. Taguchi, et al.20 
suggested that early sADT before reaching a PSA level of 0.2 
ng/mL might reduce BCR in pT2-4N0 PCa. However, their 
studies were limited due to a relatively small patient cohort and 
a lack of survival outcome analysis. 
In the present study, we reported that early sADT could have 
benefits for DPFS and DMFS. In a similar concept, very early 
salvage radiotherapy improved DMFS.21 These findings suggest 
that sADT might be particularly effective when tumor burden 
was minimal.6 
We did not exclude patients who received salvage radiother-
apy. Salvage radiotherapy was associated with DPFS or DMFS 
in our analyses; however, proportions of patients with salvage 
radiotherapy were significantly different in groups A and B. 
This difference should be considered for comparison of surviv-
als between the two groups. We will examine in the future fur-
ther details through a more precisely designed study. 
We recognize that our present study has several limitations. 
This study is retrospective and evaluated outcomes for a rela-
tively small number of patients. Additional randomized, pro-
spective multi-center studies are needed to confirm our data. 
Furthermore, because there were few mortalities and a small 
number of cases of indolent localized or regional PCa, it was 
difficult to draw a definitive association between early sADT 
and CSS. Finally, side effects associated with ADT and patient 
anxiety were not considered in the study. We recognize that 
these should be considered prior to the initiation of sADT af-
ter RP and should be included in future studies. 
Our current study aimed to identify the optimal timing for 
sADT following RP. Our findings suggest that early sADT, ad-
ministered prior to the current definition of BCR, is associated 
with improved disease progression and DMFS. In non-organ 
confined PCa, early sADT had better CSS than did delayed 
sADT. Furthermore, we demonstrated that early sADT has a 
positive impact on DPFS and DMFS. Although early sADT 
was not associated with CSS in this study, early sADT showed 
favorable CSS in non-organ confined PCa. Physicians may wish 
to consider early ADT as a salvage treatment after RP, espe-
cially in patients with non-organ confined PCa. 
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